Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | CLL14 trial thoughts

Constantine Tam • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Obinutuzumab Venetoclax
CLL14

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses his thoughts on the CLL14 trial (NCT02242942) of venetoclax-obinutuzumab among with untreated chronic lymphocytic leukemia (CLL) patients with a higher age or reduced fitness. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Constantine Tam

The combination of sonrotoclax and zanubrutinib in MCL and CLL 1:10
The combination of sonrotoclax and zanubrutinib in MCL and CLL
Constantine Tam • 31 May 2025
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial 1:20
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Constantine Tam • 31 May 2025
Five-year follow-up of SEQUOIA Arm C: zanubrutinib in patients with del(17p) CLL 2:12
Five-year follow-up of SEQUOIA Arm C: zanubrutinib in patients with del(17p) CLL
Constantine Tam • 31 May 2025
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL 1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals